| CRUSADE LABORATORIES LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20110244576 | Herpes Simplex Virus Complex - There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins. | 10-06-2011 |
| 20110195053 | Treatment of Non-Neuronal Cancer using HSV-1 Variants - A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome. | 08-11-2011 |
| 20110158948 | Treatment Using Herpes Simplex Virus - Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L. | 06-30-2011 |
| 20100272691 | Viruses - Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L. | 10-28-2010 |
| 20100172872 | Treatment of Cancer Using HSV Mutant - Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (R | 07-08-2010 |
| 20100092515 | HERPES SIMPLEX VIRUSES AND METHODS OF VIRAL REPLICATION - A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide. | 04-15-2010 |
| 20090274728 | Mutant Viruses - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses. | 11-05-2009 |
| 20090208460 | Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy. | 08-20-2009 |
| 20090176203 | Mutant HSV, Materials and Methods for Generation of Mutant HSV - A method of generating a mutant Herpes Simplex Virus (HSV) is disclosed, wherein the generated HSV genome comprises nucleic acid encoding a nucleic acid sequence of interest, the method comprising the steps of: i. providing a nucleic acid vector comprising nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences; ii. providing an HSV, the genome of which comprises third and fourth site specific recombination sequences; iii. contacting said nucleic acid vector of (i) with said HSV of (ii) together with one or more recombinase enzymes capable of catalysing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV; iv. identifying HSV containing the nucleic acid sequence of interest, wherein steps i-iii are conducted in a cell-free system. | 07-09-2009 |
| 20090010889 | Treatment Using Herpes Simplex Virus - The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed. | 01-08-2009 |
